We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassay Evaluated for Severe Neurocysticercosis

By LabMedica International staff writers
Posted on 25 Mar 2013
Print article
Image: MRI scan of a patient with neurocysticercosis (Photo courtesy of UCLA).
Image: MRI scan of a patient with neurocysticercosis (Photo courtesy of UCLA).
The potential of the secreted metacestode antigen HP10 detection enzyme-linked immunosorbent assay (HP10 Ag-ELISA) has been evaluated in the long-term follow-up in the severe form of neurocysticercosis.

The assay performance was compared with that of Magnetic Resonance Imaging (MRI) and in addition, the robustness of the HP10 Ag-ELISA was evaluated independently at two different institutions.

Scientists at the National Autonomous University of Mexico (University City, Mexico) conducted a cohort trial involving 38 neurocysticercosis (NC) with cysticerci located in the subarachnoid space at the base of the brain (NC-SaB) cases and a total of 108 paired serum and cerebrospinal fluid (CSF) samples taken at intervals of four to eight months for up to 43 months. HP10 antigen was detected by Ag-ELISA and optical densities (OD) read at 450 nm and determined in ELISA processors, either the Benchmark Microplate Reader (Bio-Rad; Hercules, CA, USA) or the Opsys MR (Dynex Technologies; Chantilly, VA, USA).

A good level of agreement was found between positive/negative allocations for paired CSF and serum samples. There was complete agreement between radiological and CSF HP10 Ag-ELISA results in 18 out of the 38 cases. Of the 108-paired MRI/HP10 Ag-ELISA evaluations, agreement between MRI and CSF HP10 Ag-ELISA was found in 76 (70.4%) cases and between MRI and sera HP10 in 65 (60%) patients. This lack of agreement appears to be principally due to a misinterpreted MRI rather than to serum and/or CSF HP10 Ag-ELISA assay and in addition, HP10 Ag-ELISA proved to be a highly reproducible method, when comparing results obtained in two different Mexican institutions.

The authors concluded that the study established the usefulness and economic advantage of the HP10 Ag-ELISA applied on CSF and serum samples for the follow-up of patients with NC-SaB, the most severe form of the disease. They believe their results will lead to the rapid commercialization of a HP10 antigen diagnostic kit to favor its employment worldwide. The study was published on March 7, 2013, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

National Autonomous University of Mexico
Bio-Rad
Dynex Technologies


New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Toxoplasma Rapid Test
Toxo IgG/IgM Rapid Test Kit
New
PROM Test
AMNIOQUICK DUO

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.